| EMA number | EMEA/H/C/000775 |
| ATC code | C09DB01 |
| Authorisation | 17 January 2007 |
| Withdrawn | 3 April 2017 |
| Revision | 20 |
Treatment of essential hypertension. Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
AMLODIPINE AND VALSARTAN — STRIDES PHARMA INTL, approved 2016-02-05 (ANDA090011).
160,115 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.